Home » News » Clinical Intelligence » The CenterWatch Weekly, September 11, 2017

The CenterWatch Weekly, September 11, 2017

Monday, September 11, 2017

Novartis gets FDA approval for first-ever CAR-T cancer therapy; other applications on the horizon

The emerging field of modifying and deploying a patient’s own cells to fight cancer just got some big legs under it with the late August approval of a new treatment for pediatric and young adult leukemia. The therapy, known as chimeric antigen receptor T cell (CAR-T), was awarded by the FDA to Novartis for Kymriah, “a novel immunocellular therapy.”

Gilead’s $12 billion acquisition of Kite ignites speculation about an M&A boom in biotech

The recent $11.9 billion acquisition of Kite Pharma by Gilead has turned up the temperature in the 2017 M&A landscape, transforming a lackluster market into one now brimming with potential as big pharma perks up and takes notice of smaller biotechs with de-risked candidates. The only other mega-deal this year has been Johnson and Johnson’s acquisition of Swiss biotech Actelion for $30 billion—the pharma giant’s biggest deal ever, which was announced in January. Yet the two deals are fundamentally different, with Gilead’s viewed as a potential market catalyst while Johnson and Johnson’s was not.


To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!